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Folding–function relationship of the most common cystic
ﬁbrosis–causing CFTR conductance mutants
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Cystic ﬁbrosis is caused by mutations in the CFTR gene, which are
subdivided into six classes. Mutants of classes III and IV reach the
cell surface but have limited function. Most class-III and class-IV
mutants respond well to the recently approved potentiator VX-
770, which opens the channel. We here revisited function and
folding of some class-IV mutants and discovered that R347P is the
only one that leads to major defects in folding. By this criterion
and by its functional response to corrector drug VX-809, R347P
qualiﬁes also as a class-II mutation. Other class-IV mutants
folded like wild-type CFTR and responded similarly to VX-809,
demonstrating how function and folding are connected. Studies
on both types of defects complement each other in under-
standing how compounds improve mutant CFTR function. This
provides an attractive unbiased approach for characterizing
mode of action of novel therapeutic compounds and helps ad-
dress which drugs are efﬁcacious for each cystic ﬁbrosis disease
variant.
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Introduction
Cystic ﬁbrosis (CF) is caused by a mutation in CFTR, an anion
channel and member of the ABC-transporter family. CFTR consists
of two transmembrane-spanning domains (TMD1 and TMD2), two
nucleotide-binding domains (NBD1 and NBD2) and an intrinsically
disordered regulatory region (R). CFTR domains mostly fold co-
translationally (Kleizen et al, 2005) and need extensive domain
assembly to form a fully functional chloride channel.
To date, more than 1,800 mutations have been identiﬁed in the
CFTR gene (http://genet.sickkids.on.ca). Most of these are not well
characterized; therefore, the CFTR2 database on CF-causing vari-
ants was created (Sosnay et al, 2013). The initial version of CFTR2
contained 159 mutations, which account for 96% of all CF patients.
Mutations in CF can be divided into six different classes: (i) defective
synthesis of full-length protein, (ii) defective protein processing
and trafﬁcking, leading to retention in the ER and degradation,
(iii) defective channel opening (gating), (iv) reduced chloride per-
meability, (v) reduced synthesis of CFTR protein, or (vi) reduced cell-
surface stability (Welsh & Smith, 1993; Castellani et al, 2008). This
classiﬁcation system is outdated because mutants can belong
to multiple classes (Veit et al, 2016). An example of this is CFTR-
F508del, a typical class-II mutant, which even when reaching the
cell surface does not function properly and shows class-III and
class-VI characteristics.
Clinical drugs targeting CFTR are divided into two types. The so-
called correctors increase cell-surface expression by improving
release from the ER (for instance by improving folding) and often
also by increasing stability at the cell surface (Yang et al, 2003;
Pedemonte et al, 2005; Van Goor et al, 2006, 2011). Compounds that
improve channel function at the cell surface are called potentiators
(Van Goor et al, 2009, 2014). Patients with class-III and class-IV
mutations (R117H, R117C, G551D, G1244E, G1349D, G178R, G551S,
S1251N, S1255P, S549N, and S549R, and several others) now have FDA
approval to be treated with the potentiator VX-770. For a wide range
of common patient mutations, VX-770 treatment improves CFTR
function (Van Goor et al, 2014).
CFTR needs to obtain the proper conformation during the folding
process to become a functional anion channel at the cell surface.
Treatments with drugs or other small molecules aim to change the
conformation in mutated proteins to a state where these can
function at least partially. Understanding the functional and folding
defects in CFTR mutants is crucial to better predict which drug
(combination) provides the best precision medicine for CF treat-
ment. CFTR function as measured by sweat-chloride concentration
in CF patients correlates well with CFTR function in organoids
derived from those patients (Dekkers et al, 2013, 2016; Noordhoek
et al, 2016). The forskolin-induced swelling assay (FIS) is used to
measure CFTR function in patient-derived organoids and is also
used to interrogate individual responses to drug treatments
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(Dekkers et al, 2013, 2016). Most CFTR2 class-IV mutants are impaired
in the formation of the pore that allows passage of anions (Mornon
et al, 2015; Linsdell, 2017). R117C/H, R334W, and R347P class-IV
mutants all have a lower overall chloride current but for differ-
ent reasons (Sheppard et al, 1993). R117H features reduced open
probability (Yu et al, 2016), whereas R347P gates like wild-type but
has a conductance below 30% of wild-type levels, and R334W has
either a very low conductance or diminished open probability
(Sheppard et al, 1993). R117 is important for maintaining the open
channel (Cui et al, 2014). The presence of many positively charged
residues in the pore of CFTR suggests their involvement in chloride
permeation. R334 has been implicated in interacting with anions at
the mouth of the pore (Smith et al, 2001), whereas R347 forms a salt
bridge that is important for maintaining an open channel (Cotten &
Welsh, 1999; Cui et al, 2013).
R117C, R117H, and R334Wmutant CFTR proteins are exported from
the ER with efﬁciencies of 49, 165, and 98% of wild-type, respectively
(Van Goor et al, 2014). By sharp contrast, R347P matures very in-
efﬁciently to ~15% of wild-type (Van Goor et al, 2014). All the pre-
viously described mutants, however, have been re-classiﬁed as
mixed class-II/III/IV (Veit et al, 2016). To address the discrepancy
between the 50% or higher maturation efﬁciency and the re-
classiﬁcations, we revisited the functional properties and folding
characteristics of the most common class-IV mutations in the
original CFTR2 database. We investigated the folding–function re-
lationship of R117C/H, R334W, and R347P using the FIS assay in
organoids, intestinal current measurements (ICMs), and radio-
labeling coupled to a protease-sensitivity assay of newly synthe-
sized CFTR. We conﬁrmed that R347P is not a “typical” class-IV
mutation. Because of its defective function and a misfolded con-
formation, it more closely resembled a class-II mutation. Folding of
the other class-IV mutants was similar, yet not identical to that of
wild-type, explaining some differences between them and doc-
umenting the strength of biochemical approaches in combination
with functional studies.
Results
R347P lacks residual function
To explore CFTR function of the class-IV mutants, we used ICM in
Ussing chambers (Fig 1). We obtained rectal biopsies of heterozy-
gous CF patients carrying one R117H, R347P, or E730X allele with
the F508del mutation on the second allele and a R334W/R746X
genotype. When CFTR is functioning properly, intestinal current
measurements yield a positive deﬂection in the short-circuit
current (Isc), reﬂecting electrogenic anion (mainly chloride) se-
cretion. In the continuous presence of the sodium-channel blocker
amiloride, elevation of intracellular cAMP by forskolin or IBMX
(3-isobutyl-1-methylxanthine) triggered a large CFTR-mediated anion
secretory current in rectal biopsies from healthy controls and from
R117H/F508del individuals (Fig 1B and E), which was reduced in
R334W/R746X (Fig 1C) and severely blunted in biopsies of R347P/
F508del patients (Fig 1A). E730X/F508del biopsies even yielded a
downward deﬂection, suggesting a net K+ secretion with little to no
CFTR activity (Fig 1D). CFTR potentiators VX-770 and/or genistein, in
the presence of saturating intracellular cAMP levels, did not further
enhance CFTR-mediated anion secretion above the level induced
by forskolin/IBMX. By contrast, the calcium-linked secretagogue
carbachol further increased the Isc, the magnitude of the response
proportional to the cAMP response. Carbachol acts mainly through
activation of basolateral K+ channels, membrane hyperpolarization,
and enhancement of the electrical driving force for chloride exit
through the CFTR channel (Fig 1A–E). Again, the response was se-
verely blunted in R347P/F508del biopsies (Fig 1A).
VX-770 does not cause swelling of R347P organoids
To conﬁrm the effect of CFTR modulators on the functional activity
of the class-IV mutants, we used the FIS assay in intestinal orga-
noids generated from rectal biopsies. Forskolin-induced activation
of CFTR causes swelling of the organoids, which we then exploit as a
readout for CFTR residual function. The outcomes of ICM and FIS
measurements correlate well (Dekkers et al, 2013; de Winter-de
Groot et al, 2018), even though each patient-derived organoid is
unique and each patient may respond differently to drug treatment
(Dekkers et al, 2016; Noordhoek et al, 2016). CF patients have two
mutated alleles for the CFTR protein and functional activity de-
pends on the type of mutation on each allele. Consequently, in
patient-derived material, both mutants likely are co-expressed,
which formally complicates analysis of how individual mutations
respond to drugs in the organoid system, analyzed in FIS and ICM
assays. To correct for the contribution of the F508del allele, we
subtracted half of the average swelling response obtained from
eight reference F508del/F508del patients (Dekkers et al, 2016).
Although EC50 values would be the preferred parameters to rate
drug effects by, this assay does not allow their reliable calculation
because CFTR mutants with low functionality respond so poorly to
forskolin that a plateau is never reached, whereas wild-type CFTR
and active mutants easily saturate the assay and plateau at ~3,200
AUC (Area Under the Curve) units because further swelling is not
possible, leading to an underestimate of the EC50. When further
swelling would be possible, the plateau would rise, moving the
apparent EC50 to the right. The maximized swelling in the FIS assay,
therefore, precludes proper readout of the EC50.
R347P/F508del was the only class-IV heterozygote that failed
to give an appreciable functional response without modulators
(Fig 2A). Importantly, preincubation of the organoids with VX-809
rescued R347P/F508del functionally, suggesting that it needs a
corrector to either reach the cell surface or function at this location.
Acute addition of VX-770 had similar effects as VX-809, but the
strongest response of R347P/F508del was seen with both treat-
ments (Fig 2A). Correction for the F508del allele (Fig 2A’) clearly
showed that the effect of VX-770 on the function of R347P is minimal
and similar to that obtained with the vehicle control. This showed
that the R347P allele can be rescued by VX-809 but not by VX-770
even when combined with VX-809.
Other class-IV mutants (R117H and R334W) showed CFTR function
under basal conditions, which was increased by VX-770, whether
corrected for the F508del allele or not (Fig 2B, B9, C, C9). The R117H/
F508del curve in the presence of modulators nears that of organoids
from healthy controls (Dekkers et al, 2016). The apparent negative
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effect of VX-809 may be due to the subtraction procedure over-
estimating the contribution of the F508del allele in this speciﬁc
patient sample. The F508del/E730X organoid was relatively inert to
VX-809 and VX-770 (Fig 2D), suggesting that the F508del allele in this
patient gained little function even upon combination of modulators.
Patients with the same genotype, however, can differ in disease
phenotype and this speciﬁc patient could have low residual function
(Dekkers et al, 2016; Pranke et al, 2017). We concluded that the class-IV
mutations on one allele contributed signiﬁcantly to the swelling of
organoids derived from these patients.
Figure 1. R347P is inactive.
ICMmeasurements of human rectal biopsies of tissues, which were treated with indicated compounds. (A) Tracing of an R347P/F508del patient showing no response upon
forskolin/IBMX addition. Even in the presence of potentiator VX-770, there was no detectable increase in signal. (B) Tracing of R117H/F508del showing a response
after addition of forskolin/IBMX. (C)Measurements of a R334W/R746X showing a slight upward deﬂection after forskolin/IBMX addition. (D) E730X/F508del patient showing
a downward deﬂection upon forskolin/IBMX addition. (E) Tracing of a healthy individual, showing a large anion secretory current after forskolin/IBMX addition.
Arrows indicate the addition of compounds: amiloride (100 μM), forskolin (10 μM), IBMX (100 μM), VX-770 (20 μM), genistein (50 μM), and carbachol (100 μM).
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Figure 2. R347P is functionally unresponsive to VX-
770.
Organoids of different patients were treated with an
increasing concentration of forskolin, and swelling was
measured after 60 min. (A) Nontreated R347P/F508del
organoids showed a low amount of swelling, indicative
for reduced CFTR function. VX-809 and VX-770 gave a
moderate response, and a combination of VX-809 and
VX-770 had an additive effect. (A9) Corrected response
of A in which 50% of the average swelling value of
F508del/F508del organoids from eight patients from
Dekkers et al (2016) was subtracted from the values
of R347P/F508del. (B) The R117H/F508del showed
residual function. VX-770 alone or a combination of
VX-770 and VX-809 gave a maximal effect, where a
plateau was reached at lower concentrations of
forskolin. (B9) R117H/F508del swelling, corrected as in
A’ (C) R334W/Mixed allele variants with F508del, R746X,
and N1303K on the second allele, had a lower but
overall similar response as R117H/F508del in B. (C’)
Same as (A9) and (B9) but subtracted from the R334W/
Mixed allele. (D) The F508del/E730X had no residual
response and a slight increase upon addition of either
drug alone, which was additive to the combination of
VX-809 and VX-770. (A–C9) Data represent average ± SD
of triplicate measurements of organoids from three
distinct patients. Data in (D) represent average ± SD of
triplicate measurements of an organoid from one
patient.
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Transport of R347P to the Golgi complex is impaired
Unlike the other tested class-IV mutants, R347P did not show ap-
preciable residual function in the ICM and FIS assays. We, therefore,
compared folding and ER-exit characteristics of R117C, R117H,
R334W, and R347P in HEK293 cells. The position of the mutations is
shown in a 3D representation of the human apo-CFTR structure (Liu
et al, 2017) (Fig 3A). The cells were labeled with 35S-methionine/
cysteine during a 15-min pulse and subsequently chased in the
presence of excess unlabeled amino acids. CFTR was immuno-
precipitated directly from detergent cell lysates or after subjecting
the lysates to limited proteolysis as detailed before (Kleizen et al,
2005; Hoelen et al, 2010).
Synthesis of CFTR takes on average 10 min, and at least another
~30 min is needed to fold the protein into a state where it can leave
the ER (Hoelen et al, 2010; Kleizen et al, 2005). Wild-type and mutant
CFTR molecules were synthesized to similar levels during the
15-min pulse (Fig 3B, top left panel) and are in the ER, where wild-
type folds into an ER-export-competent state. During the chase
period, the folded wild-type protein (Fig 3B, top right panel) is trans-
ported to the Golgi complex where its N-linked glycans are modiﬁed
into the complex-glycosylated form typical for CFTR molecules that
Figure 3. VX-770 does not improve R347P folding.
(A) Cryo-EM structure of human CFTR (Liu et al, 2017)
(PBD: 5UAK), generated using Chimera software
(Pettersen et al, 2004), illustrating that R117 is in the
cytoplasm in the ﬁrst extracellular loop between TM1
and TM2, R334 is located in the second extracellular
loop between TM3 and TM4, and R347 is located in TM6
inside the pore. The colors wheat, purple, gray, green,
and blue indicate TMD1, NBD1, R region, TMD2, and
NBD2, respectively. (B) CFTR was expressed in HEK293
cells, which were labeled with 35S-methionine/cysteine
for 15 min and chased for 0 and 2 h in the presence or
absence of 3 μM VX-770. The cells were lysed in 1%
Triton X-100 in MNT, and the cell lysates were treated or
not with Proteinase K at 25 μg/ml for 15 min. CFTR and
fragments were immunoprecipitated using TMD1C
(TMD1), Mr. Pink (NBD1 and full-length CFTR), TMD2C
(TMD2), and 596 (NBD2) antibodies. * indicates
nonspeciﬁc bands.
Source data are available online for this ﬁgure.
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have left the ER (Cheng et al, 1990; Hoelen et al, 2010). The fraction of
class-IV mutants that reached the Golgi complex was mutation
speciﬁc, where R374P left the ER least efﬁciently. For comparison, we
included F508del CFTR in the analysis (Fig 3B) as it fails to fold and
reach the Golgi complex but instead is retained in the ER and
disposed off through ER-associated degradation (Cheng et al, 1990;
Jensen et al, 1995; Ward et al, 1995; Meacham et al, 2001).
R347P is severely misfolded
We next compared the folding of the class-IV mutants with wild-
type and F508del CFTR, by subjecting detergent lysates prepared
from radioactively labeled cells to limited proteolysis followed by
immunoprecipitation with CFTR domain–speciﬁc antibodies. Pro-
teases will cleave a misfolded protein or a folding intermediate
more efﬁciently than a well-folded protein, leading to different
digestion patterns on an SDS-PAA gel (Hoelen et al, 2010; Kleizen
et al, 2005; Sharma et al, 2001; Zhang et al, 1998). Immediately after
the pulse, the TMD1 antibody immunoprecipitated three proteolytic
fragments, identical for wild-type and mutant CFTR (Fig 3B, IP:TMD1,
T1a-c). The wild-type CFTR TMD1 fragments disappeared over time
during the chase, concomitant with the appearance of three larger
(more protease-resistant, more folded) TMD1 fragments, T1d-f,
which were absent from the Class-II F508del mutant. Digestion
of the class-IV mutants gave the same three wild-type TMD1
fragments after the chase, except R347P, which only yielded a
detectable bottom fragment T1d because T1e and T1f were below
(Fig 3B) or close to (Figs 4 and 5) detection level. The NBD1 domain
was protease resistant in both pulse and chase samples of wild-
type CFTR and all four class-IV mutants (Fig 3B, IP: NBD1), with
fragment quantities relating to full-length proteins as in wild-type.
As expected, F508del NBD1 was protease sensitive (Hoelen et al,
2010). Immunoprecipitation with the TMD2 antibody showed a
prominent fragment (T2b) immediately after the pulse, whose in-
tensity decreased during 2 h of chase. In wild-type CFTR and again
three of the four class-IV mutants, TMD2 became more protease
resistant and more folded during the chase, whereas this T2c
fragment was barely detectable in the R347P and even less in the
F508del CFTR digests (Fig 3B, IP: TMD2, and Figs 4 and 5). The NBD2
protease-resistant fragment, N2a, indicative of NBD2 folding, be-
came more intense during the chase period, in wild-type CFTR and
the class-IV mutants, but again to a much lesser extent in R347P. In
the archetypical class-II F508del mutant, NBD2 remained com-
pletely protease sensitive, that is, not folded (Fig 3B, IP: NBD2).
Whereas folding of three of the class-IV mutants was similar to
that of wild-type CFTR, R347P formed a notable exception because
all its domains except NBD1 were more Proteinase K susceptible,
documenting that its domains were less well folded than in wild-
type CFTR and the other mutants (Fig 3B). Because limited pro-
teolysis of R347P yielded some TMD1, NBD1, TMD2, and NBD2
fragments that were completely absent in F508del (Fig 3B), we
concluded that R347P was slightly better folded than F508del.
Protease susceptibility of R347P’s TMD1 was different in two ways:
not only less of each fragment but also slightly larger fragments
were generated than with wild-type CFTR. All fragments except T1a
had a slightly lower mobility on SDS-PA gels (Figs 3B, 4, and 5,
TMD1b-f) because the amino-acid change affected the mobility of
each R347P-containing fragment (our unpublished observations).
Most class-IV mutants respond to VX-770 conformationally
We then assessed the biochemical effects of VX-770 and VX-809 on
the class-IV mutants and established whether improvement of
abnormal folding could explain the outcomes of the functional
experiments. Addition of VX-770 did not affect the synthesis of wild-
type CFTR or any of the mutants (Fig 3B, left panel). Whereas it
slightly decreased the transport to the Golgi of some mutants (Fig
3B, right panel), steady-state CFTR levels were not affected by 3 μM
VX-770 (Fig 4B). Limited proteolysis of the 2-h chase samples fol-
lowed by immunoprecipitation with the TMD1 antibody showed,
however, that VX-770 slightly destabilized the N terminus of TMD1 of
wild-type and the R117 and R334 mutants, as the three late frag-
ments, T1d-f, collapsed into the smallest T1d band (Fig 3B); these
fragments only differ at their N terminus (our unpublished ob-
servations). In apparent contrast, the approximately twofold in-
crease in signal of the combined T1d-f large fragments in the
presence of VX-770 (Fig 3B) conﬁrmed that VX-770 increased overall
TMD1 protease resistance (Byrnes et al, 2018). Because folding of
R117H, R117C, and R334W were wild-type–like in control and VX-
770–treated samples, we concluded that a gross conformational
defect did not account for their reduced chloride transport.
The folding defect of R347P is rescued by VX-809
Because VX-809 increased the functional response of R347P and VX-
770 had little if any effect (Fig 2A), we investigated whether VX-809
rescued folding of this mutant. The general effect of VX-809 was an
increase in quantity of CFTR, of both full-length and protease-
resistant fragments (Fig 4A–C; B. Kleizen, I. Braakman, unpublished
observations; Van Goor et al, 2011; Okiyoneda et al, 2013; Ren et al,
2013; Loo & Clarke, 2017). This strongly suggests that VX-809 helps
CFTR fold into a more protease-resistant, stable conformation. VX-
809 partially rescued F508del from the ER as seen by the ap-
pearance of a Golgi form after a chase as well as the late fragments
of TMD1, TMD2, and NBD2 mentioned previously (Fig 4A, right
panels). VX-809 did not rescue folding of F508del NBD1 as seen in
the immunoprecipitations for NBD1 (Fig 4A; Okiyoneda et al, 2013).
R347P was the only mutant that responded well functionally to VX-
809 in the FIS assay (Fig 2A and A’), which correlates with the in-
creased levels of R347P after 15 min of pulse labeling, the improved
transport to the Golgi complex (Fig 4A, top panels), and the in-
creased steady-state levels (Fig 4B).
In nontreated control conditions, limited proteolysis of the R347P
mutant yielded minute quantities of late TMD1 fragments. The
strong improvement of R347P folding and conformation by VX-809
is demonstrated by the recovery of the late TMD1 fragments, albeit
enriched for T1d (Fig 4A). The other domains also gained stability
after VX-809 treatment, which hence improved the complete
protein (Fig 4A) and its function (Fig 2A and A’). That VX-809 rescued
the R347Pmutantmore efﬁciently than F508del was likely caused by
its improving TMD1 folding, the domain that contains the R347P
mutation and hence the primary defect.
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To assess whether enhanced transport of CFTR variants to the
Golgi complex resulted in more molecules reaching the plasma
membrane, we used cell-surface biotinylation. As shown in Fig 4B,
wild-type, R117C/H, and R334W CFTRs have similar cell-surface
expression, whereas R347P and F508del CFTRs were barely or not
detectable. Plasma membrane expression was increased to a
variable extent upon VX-809 treatment (minimally for F508del),
whereas VX-770 was without effect (Fig 4B). We next investigated
whether R347P CFTR that had been rescued by VX-809 became
responsive to VX-770 (Fig 4C). In agreement with the functional
results in the FIS and ICM assays, R347P remained unresponsive to
VX-770 even though VX-809 rescued the late fragments from all
domains of R347P (Fig 4C).
The proline residue in R347P destabilizes TM6
The reduced stability of R347P is likely due to changes in trans-
membrane segment 6 (TM6) of TMD1, which contains the mutated
residue. The question is whether the loss of the charged amino acid
or gain of the proline caused the defect. To establish the role of the
proline, we used another disease-causing mutant in which R347
was changed to histidine and designed three additional mutants
(Fig 5A and B). A helical wheel representation showed that R347 is
embedded in a polypeptide stretch enriched for small hydrophobic
residues (Fig 5C). We, therefore, changed R347 to a valine or leucine,
whereas the arginine-to-glutamine wasmade because glutamine is
present at the 347th position in other ABC transporters.
The protease digestion pattern of the four mutants was similar to
that of wild-type CFTR (Fig 5A). Like in R347P, mutation to a glu-
tamine resulted in the upward shift of the T1b-f bands (Fig 5A)
because of a small change in mobility of the mutation-containing
fragments. The loss of arginine caused a small alteration in late
TMD1 fragments of all R347 mutants, with an enrichment of T1d over
T1e and T1f compared with wild-type TMD1 (Fig 5A and B). Never-
theless, relative to this minor change, the introduction of a proline
residue caused the major folding defects.
Discussion
Here, we investigated the structure–function relationship of themost
common class-IV CF-causing CFTR mutants, deﬁning a subgroup of
CF patients also known as the altered-chloride-conductance group
(Welsh & Smith, 1993; Castellani et al, 2008). CFTR mutants of this
class can escape the ER and reach the plasma membrane. Patients
with these mutations may beneﬁt from treatment with a single
potentiator drug to ’activate’ the mutant CFTR protein at the cell
surface. Patients carrying class-IV mutations, with the exception of
R117H and R117C, do not yet have clinical approval for treatment with
the VX-770 potentiator compounds. We addressed the folding
characteristics of class-IV CFTR mutants to uncover the underlying
mechanism for functional effects of VX-770 and corrector VX-809
treatment in this group and found that all responded and were
improved conformationally by VX-809. The corrector improved
folding in all mutants but barely affected R334W and R117H function,
most likely because their cell-surface levels already are at a maxi-
mum, wild-type–like level. By contrast, R347P deviated in that it
beneﬁtted well from VX-809 (in amanner distinct from F508del CFTR),
yet did not have a functional VX-770 response. Wehave shown that all
functional mutants respond to the corrector drug and that R347P
responded better to corrector than to potentiator treatment, clas-
sifying R347P as bona ﬁde class-II mutant.
An explanation of the differences between the mutants is greatly
facilitated by the recent structure models of CFTR and the cryo-EM
structures of CFTR and other ABC transporters, which enable
structure-based experimental design and analysis. The “hyper-
response” of R347P to correction is likely caused by VX-809, cor-
recting precisely where the defect is, in TMD1 (Loo et al, 2013; Loo &
Clarke, 2017; our unpublished results). R347P resides in trans-
membrane helix 6 and the cryo-EM structure of human CFTR shows
that TM6 interacts with the N terminus at the elbow helix and packs
closely to TM3 and ICL1, the ﬁrst intracellular loop in TMD1, which
interacts through its coupling helix with NBD1 in folded CFTR (Fig
5D) (Liu et al, 2017). Changing arginine 347 to a proline in TM6 will
destabilize the helix and will likely affect the packing of TM6 with
ICL1 and the N terminus (Choi et al, 2005). VX-809 was reported to
promote interactions of NBD1 with ICL1 (Loo et al, 2013; Loo & Clarke,
2017), and allosterically with ICL4 (Hudson et al, 2017; Laselva et al,
2018), both consistent with our data (Fig 4A–C) and our unpublished
results (Kleizen & Braakman, in preparation). Corrector VX-809
improves packing of TMD1, and thereby rescues interactions with
the other domains, in particular NBD1.
The destabilization of the N terminus of TMD1 was not unique to
R347P, as also VX-770 had this effect in our assays. Indeed, the N
terminus and ICL1 are affected by VX-770 to some extent (Byrnes
et al, 2018). We conclude that the amino terminus in R347P is
destabilized to such an extent that VX-770 failed to exert a sig-
niﬁcant effect in the two functional assays. Functional experiments
suggest that (heterozygous) R347P patients can beneﬁt from a
combination treatment of the two drugs, which was shown to be
beneﬁcial to F508del homozygous patients with variable improve-
ments between 4.3 and 6.7% (Wainwright et al, 2015).
Even though the introduction of the proline residue caused the
strongest defect, the highly conserved arginine does play a key role in
maintaining the open pore architecture. R347 makes a salt bridge
with aspartate residues in positions 924 and 993 of TMD2 in the open
channel (Cui et al, 2013). Removal of this arginine, therefore, causes
reduced function, as in the R347H patientmutant (Cotten&Welsh, 1999;
Figure 4. VX-809 corrects R347P folding.
(A) HEK293 cells expressing CFTR constructs were labeled for 15 min and chased for 0 or 2 h in the presence or absence of VX-809. The cells were lysed in 1% Triton X-100
in MNT, and the cell lysates were incubated with or without Proteinase K at 25 μg/ml for 15 min. CFTR and fragments were immunoprecipitated using domain-speciﬁc
antibodies as in Fig 3. (B) Cell-surface biotinylation of CFTR in HEK293 cells with or without VX-809 or VX-770 pretreatment. The cells were lysed in 1% Triton X-100 in MNT,
and the lysates were used for pull-down of biotinylated proteins with NeutrAvidin beads. 7.5% SDS-PAA gels were run and transferred to PVDF membrane and
blotted against CFTR (596) or Actin. (C) Same as in (A) but in the presence of VX-770, VX-809, or both as indicated. All lanes of IP:TMD1 were present on one gel, but the solid
black line indicates where the lanes were removed. * indicates nonspeciﬁc bands.
Source data are available online for this ﬁgure.
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VanGoor et al, 2014). R347V, L, andQCFTR also foldedwild-type–like, but
the subtle change in TMD1 as reﬂected by the enrichment of the T1d-
fragment (Fig 5A and B) suggests a subtle conformational defect at the
N terminus, consistent with the subtle functional defect of R347H CFTR
(Cotten & Welsh, 1999; Van Goor et al, 2014).
Other class-IV mutants fold largely like wild-type CFTR albeit with
some minor differences. R334 is in ECL3 with its side chain towards
TM1 (Fig 5E). This must be a more tolerant part of the molecule
because even introduction of a large aromatic residue such as Trp
does not grossly perturb folding of the protein. In the open channel
structure model (Mornon et al, 2015), R334 is located close to ECL4 in
TMD2, where R334 may have a prominent role inmaintaining a stable
open form by making a salt bridge with D891 (Sheppard et al, 1993)
and in the closed state with E217 (Rahman et al, 2013) (Fig 5E and F).
The lack of differences between wild-type CFTR and the R117
mutants suggested that the gross conformation of the channel is
not altered. R117 is in the ﬁrst extracellular loop (ECL1) of TMD1 at
the beginning of TM2 (Fig 5D and F) and creates or stabilizes the
open channel through a salt bridge with E1126 (Sheppard et al, 1993;
Rahman et al, 2013; Cui et al, 2014; Yu et al, 2016). Lack of large
structural effects in both ECL mutants suggests a minor role of ECLs
in overall folding but a major role in maintaining an open pore.
An increasing number of human diseases are known to be
caused by misfolding of mutant ABC transporters (Theodoulou &
Kerr, 2015). Screens for small molecule treatments have been in-
stigated, including for Tangier disease (ABCA1), gout (ABCG2),
Stargardt eye disease (ABCA4), progressive familial intrahepatic
cholestasis type 2 (ABCB11) (Allikmets et al, 1997; Strautnieks et al,
1998; Rust et al, 1999; Woodward et al, 2009), and congenital
hyperinsulinemia (Chen et al, 2013). Unlike the last example where
carbamazepine corrects the folding of the sulfonylurea receptor 1,
corrector compounds and robust functional readouts are not as
readily available for most ABC-transporter diseases as for CFTR.
In those cases, an in-depth analysis of the folding–function re-
lationship of the target protein provides an attractive approach for
characterization of the mode of action of novel therapeutic com-
pounds as we have shown here for CFTR.
Materials and Methods
Reagents
VX-809 and VX-770 (Selleckchem) were dissolved in DMSO and
stored at −80°C. Amiloride, forskolin, genistein, carbachol,
4,49-diisothiocyano-2,29-stilbenedisulfonic acid (all from Sigma-
Aldrich) were dissolved in water and stored at −20°C. Linear 40-
kD polymer polyethylenimine (Polysciences) was dissolved in water
to 1 mg/ml, pH 7.0; this solution will be referred to as PEI from now
on. The rabbit antibody Mr. Pink andmousemonoclonal 596 against
CFTR have been characterized before (Gentzsch et al, 2003; Hoelen
et al, 2010). The antibodies TMD1C and TMD2C were generated in
rabbits against KLH-coupled peptides SLGAINKIQDFLQKQEYK and
EGKPTKSTKPYKNGQ, respectively.
Mutations in R347V, R347L, and R347Q were made from pBi.CMV2-
CFTR template with site-directed mutagenesis, using primers 59
ctgcattgttctggtcatggcggtcactc 39, 59 ctgcattgttctgctcatggcggtcactc 39,
and 59 ctgcattgttctgcagatggcggtcactc 39, respectively.
Cell culture and transient expression
HEK293 cells were maintained in DMEM supplemented with 10%
fetal bovine serum (qualiﬁed, E.U.–approved, South America origin)
and 2 mM GlutaMAX at 37°C and 5% CO2 unless speciﬁed otherwise.
All reagents were purchased from Life Technologies. cDNA encoding
wild-type or mutant CFTR was introduced in the NotI site of the
bicistronic plasmid pBi.CMV2 (Clontech), which also drives ex-
pression of GFP. HEK293 cells were grown in 6- or 3.5-cm dishes to
~70% conﬂuency and transfected using PEI. 5 μg of DNA was added
to 200 μl 150 mM NaCl and 12.5 μl PEI for 6-cm dishes and 2.5 μg DNA
was added to 100 μl 150 mM NaCl and 7.5 μl PEI for 3.5-cm dishes;
these solutions were incubated for 10 min at RT. The cells were then
grown in DMEM supplemented with 5% FBS and 1mMGlutaMAX, and
DNA:PEI complexes were added. After 4 h, the medium was aspi-
rated and replaced with full growth medium.
Pulse-chase analysis
HEK293 cells were used 24 h post-transfection for pulse-chase
experiments as described (Braakman et al, 1991; Hoelen et al,
2010). Brieﬂy, the cells were labeled for 15 min with 143 μCi/6-cm
dish of EasyTag Express 35S-protein-labeling mix (Perkin Elmer).
Label incorporation was stopped by adding an excess unlabeled
cysteine and methionine. At indicated chase times, dishes were
transferred to ice and washed twice with ice-cold HBSS (Life
Technologies). The cells were lysed using 1% Triton X-100 in MNT
(20 mM MES, 100 mM NaCl, and 30 mM Tris–HCl, pH 7.5). The lysates
were cleared by centrifugation at 16,000 g and 4°C. The supernatant
was used for limited proteolysis or immunoprecipitation as de-
scribed (Jansens et al, 2002). Where indicated, VX-770 or VX-809 was
Figure 5. The proline in R347P destabilizes TM6.
(A) As in Fig 3B, HEK293 cells transiently expressing indicated CFTR constructs were labeled for 15 min and chased for 0 or 2 h. The cells were lysed in 1% Triton X-100 in MNT
and incubated with proteinase K for 15 min, followed by immunoprecipitation of CFTR with domain-speciﬁc antibodies. The lane labeled C is a nontransfected control.
* indicates nonspeciﬁc bands. (B) Lane proﬁles of IP:TMD1 data shown in (A). (C) Helical wheel representation of CFTR residues 331–360, showing that R347 is largely
surrounded by small hydrophobic residues. Hydrophilic (circle), hydrophobic (diamond), negatively charged (triangle), positively charged (pentagons). Shades of green
indicate the hydrophobicity with dark green having high hydrophobicity and yellow zero hydrophobicity. Hydrophilic residues are shades of red, more intense red means
most hydrophilic residue. Potentially charged residues are light blue. (D) Cryo-EM structure of human CFTR illustrating R347 and interacting residues, helices are shown as
cylinders (Liu et al, 2017) (PBD: 5UAK). R347 is highlighted in red, and its interacting residues D993 and D924 are colored yellow. Transmembrane helix 6 and the N terminus
(AA 1–77) are colored in light blue. Extracellular loops and intracellular loop 1 (ICL1) are labeled in dark gray. The colors wheat, blue, gray, green, and purple indicate TMD1,
NBD1, R region, TMD2, and NBD2, respectively. The arrow indicates rotation in relation to Fig 3A left panel. (E) Same as in D, R117 in ECL1 and R334 in ECL2 are shown as red
spheres, and their interacting residues E1126 in ECL5 and E217 in ECL3 are represented as yellow spheres. (F) Structural model of CFTR in the open conformation (Mornon
et al, 2015), illustrating R117 and R334 in red along with their binding partners in yellow. Colors and annotations are the same as in (D, E).
Source data are available online for this ﬁgure.
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added to 3 μM (ﬁnal concentration) medium during starvation,
pulse, and chase.
Limited proteolysis
Limited proteolysis was performed as described (Kleizen et al, 2005;
Hoelen et al, 2010). In short, detergent cell lysates were digested
for 15 min on ice, using 25 μg/ml proteinase K (Sigma-Aldrich).
The reaction was stopped by adding an equal volume of MNT
supplemented with 1% Triton X-100, 2 mM PMSF, and 2 μg/ml of
chymostatin, leupeptin, antipain, and pepstatin A (CLAP; all from
Sigma-Aldrich).
Immunoprecipitation
Following limited proteolysis, the samples were transferred to 50 μl
of protein-A beads (GE Healthcare) that had been preincubated
with the antibody for 10 min at 4°C. All immunoprecipitates were
washed twice for 10 min at RT. Proteolytic fragments originating
from TMD1 were immunoprecipitated with 4 μl of TMD1C antibody,
added to protein-A beads, incubated for 3 h at 4°C, andwashedwith
10 mM Tris–HCl, pH 8.6, 300 mM NaCl, 0.05% SDS, and 0.05% Triton
X-100. NBD1 fragments were immunoprecipitated with 5 μl of Mr.
Pink antibody and incubated overnight at 4°C. The immunopre-
cipitates were washed with 10 mM Tris–HCl, pH 8.6, 300 mM NaCl,
0.1% SDS, and 0.05% Triton X-100. Fragments derived from TMD2
were immunoprecipitated with 4 μl of TMD2C antibody for 3 h at 4°C
and washed with 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 1 mM
EDTA. NBD2-derived fragments were immunoprecipitated with
0.25 μl 596 antibody and incubated for 3 h at 4°C and washed using
30 mM Tris–HCl, pH 7.5, 20 mM MES, 100 mM NaCl, and 0.5% Triton
X-100. Washed immunoprecipitates received 10 μl 10 mM Tris–HCl,
pH 6.8, and 10 μl 2× reducing Laemmli sample buffer and were
heated for 5 min at 55°C.
Cell-surface biotinylation
Four hours post-transfection, the cells received fresh medium
containing 3 μM VX-770, 3 μM VX-809, or no drug and were sub-
sequently grown for 16 h. The dishes were transferred to ice and
washed twice with PBS++ (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4,
2 mM KH2PO4, 1 mM CaCl2, and 0.5 mM MgCl2) and left to cool for
15 min. Buffer was aspirated, and 500 μl PBS++ containing 0.5 mg/ml
sulfo-NHS-SS-biotin (Thermo Fisher Scientiﬁc) was added and
incubated on ice After 30 min; the buffer was removed and
remaining nonreacted sulfo-NHS-SS-biotin was quenched by
washing twice with 1% BSA in PBS++ (Sigma-Aldrich). The cells were
lysed in 300 μl MNT containing 1% Triton X-100, 1 mM CLAP, and 1mM
PMSF. The lysates were cleared by centrifugation at 16,000g and
4°C. Directly after centrifugation, 10 μl of the lysate was transferred
to an equal volume of 2× reducing Laemmli sample buffer and
saved as input sample. The remaining lysate was incubated with
25 μl NeutrAvidin beads (Thermo Fisher Scientiﬁc) for 1 h. The
NeutrAvidin beads were washed twice with 10 mM Tris–HCl, pH 8.6,
300mMNaCl, 0.1% SDS, and 0.05% Triton X-100 before receiving 15 μl
of 10 mM Tris–HCl, pH 6.8, and 15 μl of 2× reducing Laemmli sample
buffer. The samples were resolved by SDS–PAGE and analyzed by
Western blot.
Western blot
The samples were run on 7.5% SDS-PAA gels and transferred to PVDF
membrane (Millipore) under 38 V for 18-21 h at 4 degrees. After
transfer blots were rinsed in PBS (137 mM NaCl, 2.7 mM KCl, 8 mM
Na2HPO4, and 2 mM KH2PO4; 1 mm) and ultrapure water, they were
subsequently incubated in LiCoR block buffer, diluted 1:1 in PBS
(BB), for 1 h at RT. CFTR was detected using 596 (1:5,000) and actin
with rabbit anti-actin (1:5,000; Sigma-Aldrich) in BB with 0.1%
Tween-20 for 1 h at RT. The blots were washed four times in PBS
containing 0.1% Tween-20 before incubation with goat-anti-mouse
Alexa-800 (1:10,000; LiCoR) and donkey-anti-rabbit Alexa-680
(1:10,000; LiCoR) in BB supplemented with 0.1% Tween-20 and
0.02% SDS for 1 h at RT. Before imaging, the blots were washed as
before with an additional wash step in PBS before imaging on LiCoR
Odyssey CLx according to the manufacturer’s speciﬁcations.
ICMs
Transepithelial chloride secretion in human rectal biopsies (four
per subject) was measured as described (De Jonge et al, 2004), with
a prewash modiﬁcation (De Boeck et al, 2011) to enhance the
forskolin-induced anion secretion. Brieﬂy, the biopsies were kept in
PBS on ice and mounted in micro-Ussing chambers (aperture 1.13
or 1.77 mm2). After the chambers were equilibrated, the compounds
were added to the mucosal (M) or serosal (S) side in the following
order: (1) amiloride (0.1 mM, M) to block amiloride-sensitive elec-
trogenic Na+ absorption, (2) forskolin (10 μM, M+S) plus 3-Isobutyl-
1-methylxanthine (100 μM, M+S) to activate CFTR dependent
chloride secretion, (3) VX-770 (20 μM, M+S) and/or genistein (50 μM,
M+S) for potentiation of CFTR channels, and (5) carbachol (100 μM, S)
to activate basolateral Ca2+-dependent K+ channels and increase
the electrochemical driving force for CFTR-mediated chloride se-
cretion. Isc values (μA) were divided by the surface area of the
tissue holder to obtain μA⋅cm−2.
Crypt isolation and organoid culture from human rectal biopsies
Crypt isolation and culture of human intestinal organoids has been
described (Sato et al, 2011; Dekkers et al, 2013). Biopsies obtained for
ICMs were washed with 10mM EDTA in PBS for 30 (small intestine) or
90–120 (rectum) min. at 4°C. The supernatant was discarded and
EDTA was washed away. Crypts were isolated by rapid up-and-down
pipetting of the biopsies in clean PBS, upon which crypts are re-
leased from the tissue. The isolated crypts in PBS were transferred
to a clean tube, centrifuged at 130 g, and embedded in 50%Matrigel
(growth factor reduced, phenol free, BD Bioscience) and seeded
(30 μl Matrigel per well, 50–200 crypts) in 24-well plates. Afterward,
Matrigel was solidiﬁed by incubation for a minimum of 15 min at
37°C and then DMEM/F12 advanced medium was added, supple-
mented with Primocin 100 μg/ml, 2 mM GlutaMax, N2, B27 (all from
Invitrogen), 1 μM N-acetylcysteine (Sigma-Aldrich), and the fol-
lowing growth factors: 50 ng/ml mouse epidermal growth factor,
50% Wnt3a-conditioned medium and 10% Noggin-conditioned
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medium, 20% Rspo1-conditioned medium, 10 μM nicotinamide
(Sigma-Aldrich), 10 nM gastrin (Sigma-Aldrich), 500 nM A83-01
(Tocris), and 10 μM SB202190 (Sigma-Aldrich). The medium was
refreshed every 2–3 d, and organoids were passaged every 7–10 d.
FIS assay
Organoids from 7-d-old cultures were plated in 4 μl of 50% Matrigel
into a 96-well ﬂat bottom plate (Nunc) immersed in 100 μl of culture
medium as described earlier. 1 d after seeding, the organoids were
stained with 10 μM calcein green for 30 min. Forskolin was added at
indicated concentrations, and the swelling was monitored for 1 h;
images were captured every 10 min, using a live-cell confocal
microscope (LSM710, Zeiss, 5× magniﬁcation). VX-809 (3 μM) was
preincubated 20–24 h before measurement, whereas VX-770 (3 μM)
was added directly. FIS was quantiﬁed using Volocity imaging
software (Improvision). Organoid surface area (xy plane) at t =
60min was calculated relative to that of the surface area at t = 0 and
averaged over three biological replicates per condition. The AUC
was calculated using Prism (GraphPad). Graphs were produced in
Tibco Spotﬁre (Perkin Elmer).
Other methods
CFTR structure from (Liu et al, 2017) PDB: 5UAK and structural model
from (Mornon et al, 2015). Images of protein structures were generated
using Chimera software (Pettersen et al, 2004), and helical wheel
representations were made using http://www.tcdb.org/progs/
helical_wheel.php. Western blot images were processed using
Image Studio 5.2 (LiCoR).
Human material
Approval for this study was obtained by the ethics committees of
the University Medical Center Utrecht and Erasmus MC Rotterdam.
Consent was obtained from all subjects participating in the present
study. Rectal organoids were generated from biopsies after ICMs
were obtained during standard cystic ﬁbrosis care.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201800172.
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